DOCSLIB.ORG

Identification and Characterisation of Rare CACNG5 Genetic Variants in Bipolar Disorder and Schizophrenia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification and Characterisation of Rare CACNG5 Genetic Variants in Bipolar Disorder and Schizophrenia Identification and characterisation of rare CACNG5 genetic variants in bipolar disorder and schizophrenia Thesis submitted for the degree of Doctor of Philosophy UCL Yi-Chun Lin Molecular Psychiatry Laboratory University College London 2010 – 2015 1 I, Yi-Chun Lin, confirm that all the work presented in this thesis is my own. I confirm that the information has been derived from other sources; it has been indicated in the thesis. 2 Acknowledgements This thesis would not have been completed without the help and support of colleagues and friends to whom I would now like to express my sincere thanks First and foremost of my thanks goes to my supervisor Dr Andrew McQuillin, who gave me this wonderful and exciting opportunity to carry out this PhD. His encouragement has provided tremendous support throughout my PhD. I am extremely grateful for his insightful advice, patience and kindness. I would also like to express my appreciation and thanks to Professor Hugh Gurling, my second supervisor, who provided further guidelines and support to enable me to complete this PhD research. Very special thanks to Dr. Radhika Kandaswamy and Dr. Sally Sharp, who have been guiding me with infinite patience in my experimental studies. I am indebted to them for their enthusiasm and advice, their friendship and support leading to the completion of research experiments. Also I would like to thank all my colleagues from my lab Michael, John, Alessia for their support. Finally, I would also like to thank my family, especially my parents for their financial support and my friends for their encouragement and support. 3 Abstract Schizophrenia (SCZ) and bipolar disorder (BPD) are common, highly heritability psychiatric disorders. Genome-wide association studies have found evidence of shared genetic susceptibility to both diseases. The most notable example is CACNA1C which encodes the 1 subunit of L-type calcium channels. Several other calcium channel genes have also been implicated in BPD and/or SCZ and together there is support for a role for these genes in both diseases. The primary function of several subunit calcium channel genes appears to be the regulation of AMPA receptor localisation and function. Collectively these are known as Transmembrane AMPA receptor Regulatory Proteins (TARPs). This thesis aimed to identify disease relevant genetic variation in one such TARP, CACNG5, and to study the effect of these variants. CACNG5 variants in the exons and promoter region were identified in 1098 BPD, 618 SCZ, and 1087 control individuals. Four novel non-synonymous SNPs (nsSNPs) and four nsSNPs were identified. Burden analysis of nsSNPs in BPD and SCZ found evidence for association (p=0.0022). This association was strengthened by inclusion of data from European samples in the 1000 Genomes project (p=0.00057). However, combined data with the UK10K and Swedish exome sequence studies founds a weakened association signal (p=0.0082). Functional analyses using co-expression of AMPAR2 and CACNG5 constructs containing the eight nsSNPs were used to analyse changes in the expression and/or trafficking of 5 and AMPA receptors. Four of the variants were associated with decreased AMPAR2 expression as a consequence of altered trafficking to the cell surface. V146M (identified in 2 SCZ patients) overexpression increased AMPAR2 trafficking to the cell surface (p<0.005); conversely, T164L (identified in one SCZ patient) overexpression decreased the expression 4 of AMPAR2 and its cell surface trafficking (p<0.05). Our results suggest a role for CACNG5 variants in SCZ and/or BPD and that this may be mediated via dysregulation of AMPARs. 5 Table of Contents Acknowledgements ................................................................................................................... 3 Abstract ..................................................................................................................................... 4 Table of Contents ...................................................................................................................... 6 Table of Tables ....................................................................................................................... 11 Table of Figures ...................................................................................................................... 14 1 Introduction ..................................................................................................................... 28 1.1 Psychiatric disorders ................................................................................................ 28 1.1.1 Overview ........................................................................................................... 28 1.1.2 History of psychiatric disorders ........................................................................ 29 1.1.3 Diagnosis of psychiatric disorders .................................................................... 31 1.1.3.1 Diagnosis of bipolar disorder ............................................................................ 33 1.1.4 Epidemiology similarities in BPD and SCZ ..................................................... 37 1.1.5 Treatment .......................................................................................................... 40 1.1.6 Pathophysiology of BPD and SCZ ................................................................... 44 1.1.7 Heritability of BPD and SCZ ............................................................................ 46 1.2 Molecular Genetics Studies ...................................................................................... 49 1.2.1 Factors affecting genetic studies ....................................................................... 51 1.2.2 Genetic Markers ................................................................................................ 53 1.2.3 Linkage analysis................................................................................................ 54 1.2.4 Association studies............................................................................................ 58 1.2.5 Summary ........................................................................................................... 62 1.2.6 Genome-wide association studies ..................................................................... 63 1.2.7 Chromosomal Rearrangements and CNV ......................................................... 74 1.3 Voltage-gated calcium channel (VGCC) ................................................................. 78 1.3.1 Ca2+ channel γ subunits ..................................................................................... 80 1.4 Glutamate receptors.................................................................................................. 85 6 1.4.1 AMPA receptors ............................................................................................... 87 1.4.2 Trafficking of AMPARs at synapses ................................................................ 95 1.4.3 TARPs as auxiliary protein of AMPARs .......................................................... 96 1.4.4 Trafficking of AMPARs associated with neuro-disorders .............................. 106 2 Aims of the thesis.......................................................................................................... 107 3 MATERIALS AND METHODS .................................................................................. 108 3.1 General Materials and Methods ............................................................................. 108 3.1.1 Research participants – UCL Research sample .............................................. 108 3.1.2 DNA Quantification ........................................................................................ 109 3.2 Variant detection and genotyping .......................................................................... 110 3.2.1 High Resolution Melting Curve Genotyping Assay ....................................... 111 3.2.2 Polymerase Chain Reaction (PCR) ................................................................. 119 3.2.3 Agarose gel electrophoresis ............................................................................ 124 3.2.4 PCR purification ............................................................................................. 125 3.2.5 DNA sequencing ............................................................................................. 127 3.2.6 KASPar Genotyping Assay............................................................................. 131 3.2.7 Association study – burden analysis ............................................................... 142 3.2.8 Bioinformatical analysis ................................................................................. 143 3.3 Preparation of CACNG5 and AMPAR2 Constructs ............................................... 144 3.3.1 Plasmid vectors ............................................................................................... 146 3.3.2 Sub-cloning of CACNG5 inserts into pCMV-Tag4 vectors via traditional restriction sites .............................................................................................................. 154 3.3.3 Sub-cloning of CACNG5 inserts into pTagRFP-C vector via PCR amplification ……………………………………………………………………………….158 3.3.4 Mutating the CACNG5 gene with each variant individually .......................... 161 3.3.5 Large-scale preparation of plasmid DNA ......................................................
Load more

Recommended publications
  • Genetic Analysis of the Calcineurin Pathway Identifies Members of the EGR Gene Family, Specifically EGR3, As Potential Susceptibility Candidates in Schizophrenia
    Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia Kazuo Yamada*, David J. Gerber†, Yoshimi Iwayama*, Tetsuo Ohnishi*, Hisako Ohba*, Tomoko Toyota*, Jun Aruga‡, Yoshio Minabe*§, Susumu Tonegawa†¶, and Takeo Yoshikawa*ʈ** Laboratories for *Molecular Psychiatry and ‡Comparative Neural Development, RIKEN Brain Science Institute, Saitama 351-0198, Japan; †Howard Hughes Medical Institute and RIKEN–MIT Neuroscience Research Center, The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139; §Department of Psychiatry and Neurology, Kanazawa University School of Medicine, Ishikawa 920-8641, Japan; and ʈCore Research for Evolutional Science and Technology, Japan Science and Technology Agency, Saitama 332-0012, Japan Contributed by Susumu Tonegawa, December 7, 2006 (sent for review September 22, 2006) The calcineurin cascade is central to neuronal signal transduction, cineurin is particularly enriched in the CNS, where it plays a critical and genes in this network are intriguing candidate schizophrenia role in the regulation of a diverse array of neuronal functions (5, 6). susceptibility genes. To replicate and extend our previously re- Interestingly, calcineurin is positioned downstream of dopaminer- ported association between the PPP3CC gene, encoding the cal- gic signaling (7) and is involved in NMDA receptor-mediated cineurin catalytic ␥-subunit, and schizophrenia, we examined 84 synaptic plasticity (8) and could therefore provide an important SNPs from 14 calcineurin-related candidate genes for genetic as- functional link between these two neurotransmitter systems. To sociation by using 124 Japanese schizophrenic pedigrees. Four of further explore the involvement of calcineurin dysfunction in these genes (PPP3CC, EGR2, EGR3, and EGR4) showed nominally schizophrenia, we have tested for genetic association of a subset of significant association with schizophrenia.
    [Show full text]
  • Nuclear and Mitochondrial Genome Defects in Autisms
    UC Irvine UC Irvine Previously Published Works Title Nuclear and mitochondrial genome defects in autisms. Permalink https://escholarship.org/uc/item/8vq3278q Journal Annals of the New York Academy of Sciences, 1151(1) ISSN 0077-8923 Authors Smith, Moyra Spence, M Anne Flodman, Pamela Publication Date 2009 DOI 10.1111/j.1749-6632.2008.03571.x License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California THE YEAR IN HUMAN AND MEDICAL GENETICS 2009 Nuclear and Mitochondrial Genome Defects in Autisms Moyra Smith, M. Anne Spence, and Pamela Flodman Department of Pediatrics, University of California, Irvine, California In this review we will evaluate evidence that altered gene dosage and structure im- pacts neurodevelopment and neural connectivity through deleterious effects on synap- tic structure and function, and evidence that the latter are key contributors to the risk for autism. We will review information on alterations of structure of mitochondrial DNA and abnormal mitochondrial function in autism and indications that interactions of the nuclear and mitochondrial genomes may play a role in autism pathogenesis. In a final section we will present data derived using Affymetrixtm SNP 6.0 microar- ray analysis of DNA of a number of subjects and parents recruited to our autism spectrum disorders project. We include data on two sets of monozygotic twins. Col- lectively these data provide additional evidence of nuclear and mitochondrial genome imbalance in autism and evidence of specific candidate genes in autism. We present data on dosage changes in genes that map on the X chromosomes and the Y chro- mosome.
    [Show full text]
  • AGAP1 (NM 014914) Human Recombinant Protein Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP314836 AGAP1 (NM_014914) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Recombinant protein of human ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 (AGAP1), transcript variant 2 Species: Human Expression Host: HEK293T Tag: C-Myc/DDK Predicted MW: 88.9 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_055729 Locus ID: 116987 UniProt ID: Q9UPQ3 RefSeq Size: 4078 Cytogenetics: 2q37.2 RefSeq ORF: 2412 Synonyms: AGAP-1; CENTG2; cnt-g2; GGAP1 Summary: This gene encodes a member of an ADP-ribosylation factor GTPase-activating protein family involved in membrane trafficking and cytoskeleton dynamics. This gene functions as a direct regulator of the adaptor-related protein complex 3 on endosomes. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2011] This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 AGAP1 (NM_014914) Human Recombinant Protein – TP314836 Protein Pathways: Endocytosis Product images: Coomassie blue staining of purified AGAP1 protein (Cat# TP314836).
    [Show full text]
  • SPATA33 Localizes Calcineurin to the Mitochondria and Regulates Sperm Motility in Mice
    SPATA33 localizes calcineurin to the mitochondria and regulates sperm motility in mice Haruhiko Miyataa, Seiya Ouraa,b, Akane Morohoshia,c, Keisuke Shimadaa, Daisuke Mashikoa,1, Yuki Oyamaa,b, Yuki Kanedaa,b, Takafumi Matsumuraa,2, Ferheen Abbasia,3, and Masahito Ikawaa,b,c,d,4 aResearch Institute for Microbial Diseases, Osaka University, Osaka 5650871, Japan; bGraduate School of Pharmaceutical Sciences, Osaka University, Osaka 5650871, Japan; cGraduate School of Medicine, Osaka University, Osaka 5650871, Japan; and dThe Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan Edited by Mariana F. Wolfner, Cornell University, Ithaca, NY, and approved July 27, 2021 (received for review April 8, 2021) Calcineurin is a calcium-dependent phosphatase that plays roles in calcineurin can be a target for reversible and rapidly acting male a variety of biological processes including immune responses. In sper- contraceptives (5). However, it is challenging to develop molecules matozoa, there is a testis-enriched calcineurin composed of PPP3CC and that specifically inhibit sperm calcineurin and not somatic calci- PPP3R2 (sperm calcineurin) that is essential for sperm motility and male neurin because of sequence similarities (82% amino acid identity fertility. Because sperm calcineurin has been proposed as a target for between human PPP3CA and PPP3CC and 85% amino acid reversible male contraceptives, identifying proteins that interact with identity between human PPP3R1 and PPP3R2). Therefore, identi- sperm calcineurin widens the choice for developing specific inhibitors. fying proteins that interact with sperm calcineurin widens the choice Here, by screening the calcineurin-interacting PxIxIT consensus motif of inhibitors that target the sperm calcineurin pathway. in silico and analyzing the function of candidate proteins through the The PxIxIT motif is a conserved sequence found in generation of gene-modified mice, we discovered that SPATA33 inter- calcineurin-binding proteins (8, 9).
    [Show full text]
  • Targeted Resequencing Identifies Genes with Recurrent Variation In
    www.nature.com/npjgenmed ARTICLE OPEN Targeted resequencing identifies genes with recurrent variation in cerebral palsy C. L. van Eyk 1,2, M. A. Corbett 1,2, M. S. B. Frank 1,2, D. L. Webber1,2, M. Newman3, J. G. Berry 1,2, K. Harper1,2, B. P. Haines1,2, G. McMichael1,2, J. A. Woenig1,2, A. H. MacLennan1,2 and J. Gecz 1,2,4* A growing body of evidence points to a considerable and heterogeneous genetic aetiology of cerebral palsy (CP). To identify recurrently variant CP genes, we designed a custom gene panel of 112 candidate genes. We tested 366 clinically unselected singleton cases with CP, including 271 cases not previously examined using next-generation sequencing technologies. Overall, 5.2% of the naïve cases (14/271) harboured a genetic variant of clinical significance in a known disease gene, with a further 4.8% of individuals (13/271) having a variant in a candidate gene classified as intolerant to variation. In the aggregate cohort of individuals from this study and our previous genomic investigations, six recurrently hit genes contributed at least 4% of disease burden to CP: COL4A1, TUBA1A, AGAP1, L1CAM, MAOB and KIF1A. Significance of Rare VAriants (SORVA) burden analysis identified four genes with a genome-wide significant burden of variants, AGAP1, ERLIN1, ZDHHC9 and PROC, of which we functionally assessed AGAP1 using a zebrafish model. Our investigations reinforce that CP is a heterogeneous neurodevelopmental disorder with known as well as novel genetic determinants. npj Genomic Medicine (2019) ; https://doi.org/10.1038/s41525-019-0101-z4:27 1234567890():,; INTRODUCTION is likely also due in part to the stringent criteria used to select Cerebral palsy (CP) is the most common motor disability of causative variants.
    [Show full text]
  • Landscape Genomic Approach to Investigate Genetic Adaptation in South African Indigenous Goat Populations by Khanyisile Mdladla
    Landscape genomic approach to investigate genetic adaptation in South African indigenous goat populations by Khanyisile Mdladla Submitted in fulfilment of the academic requirements of Doctor of Philosophy in Genetics School of Life Sciences College of Agriculture, Engineering and Science University of KwaZulu-Natal Pietermaritzburg South Africa December 2016 PREFACE The research contained in this thesis was completed by the candidate while based in the Biotechnology Platform, Agricultural Research Council and the Discipline of Genetics, School of Life Sciences of the College of Agriculture, Engineering and Science, University of KwaZulu-Natal, Pietermaritzburg, South Africa. The research was financially supported by University of KwaZulu-Natal, National Research Foundation-Department of Science and Technology (NRF-DST) and the Agricultural Research Council. The contents of this work have not been submitted in any form to another university and, except where the work of others is acknowledged in the text, the results reported are due to investigations by the candidate. _________________________ Signed: Edgar Farai Dzomba Date: _________________________ Signed: Farai Catherine Muchadeyi Date: i DECLARATION 1: PLAGIARISM Note that two declaration sections are required if there are papers emanating from the dissertation/thesis. The first (obligatory) declaration concerns plagiarism and the second declaration specifies your role in the published papers. I, Khanyisile Mdladla declare that: (i) the research reported in this dissertation, except where otherwise indicated or acknowledged, is my original work; (ii) this dissertation has not been submitted in full or in part for any degree or examination to any other university; (iii) this dissertation does not contain other persons’ data, pictures, graphs or other information, unless specifically acknowledged as being sourced from other persons; (iv) this dissertation does not contain other persons’ writing, unless specifically acknowledged as being sourced from other researchers.
    [Show full text]
  • Targeting PH Domain Proteins for Cancer Therapy
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2018 Targeting PH domain proteins for cancer therapy Zhi Tan Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Bioinformatics Commons, Medicinal Chemistry and Pharmaceutics Commons, Neoplasms Commons, and the Pharmacology Commons Recommended Citation Tan, Zhi, "Targeting PH domain proteins for cancer therapy" (2018). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 910. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/910 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. TARGETING PH DOMAIN PROTEINS FOR CANCER THERAPY by Zhi Tan Approval page APPROVED: _____________________________________________ Advisory Professor, Shuxing Zhang, Ph.D. _____________________________________________
    [Show full text]
  • An Integrated Genomic Analysis of Gene-Function Correlation on Schizophrenia Susceptibility Genes
    Journal of Human Genetics (2010) 55, 285–292 & 2010 The Japan Society of Human Genetics All rights reserved 1434-5161/10 $32.00 www.nature.com/jhg ORIGINAL ARTICLE An integrated genomic analysis of gene-function correlation on schizophrenia susceptibility genes Tearina T Chu and Ying Liu Schizophrenia is a highly complex inheritable disease characterized by numerous genetic susceptibility elements, each contributing a modest increase in risk for the disease. Although numerous linkage or association studies have identified a large set of schizophrenia-associated loci, many are controversial. In addition, only a small portion of these loci overlaps with the large cumulative pool of genes that have shown changes of expression in schizophrenia. Here, we applied a genomic gene-function approach to identify susceptibility loci that show direct effect on gene expression, leading to functional abnormalities in schizophrenia. We carried out an integrated analysis by cross-examination of the literature-based susceptibility loci with the schizophrenia-associated expression gene list obtained from our previous microarray study (Journal of Human Genetics (2009) 54: 665–75) using bioinformatic tools, followed by confirmation of gene expression changes using qPCR. We found nine genes (CHGB, SLC18A2, SLC25A27, ESD, C4A/C4B, TCP1, CHL1 and CTNNA2) demonstrate gene-function correlation involving: synapse and neurotransmission; energy metabolism and defense mechanisms; and molecular chaperone and cytoskeleton. Our findings further support the roles of these genes in genetic influence and functional consequences on the development of schizophrenia. It is interesting to note that four of the nine genes are located on chromosome 6, suggesting a special chromosomal vulnerability in schizophrenia.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Ce Document Est Le Fruit D'un Long Travail Approuvé Par Le Jury De Soutenance Et Mis À Disposition De L'ensemble De La Communauté Universitaire Élargie
    AVERTISSEMENT Ce document est le fruit d'un long travail approuvé par le jury de soutenance et mis à disposition de l'ensemble de la communauté universitaire élargie. Il est soumis à la propriété intellectuelle de l'auteur. Ceci implique une obligation de citation et de référencement lors de l’utilisation de ce document. D'autre part, toute contrefaçon, plagiat, reproduction illicite encourt une poursuite pénale. Contact : [email protected] LIENS Code de la Propriété Intellectuelle. articles L 122. 4 Code de la Propriété Intellectuelle. articles L 335.2- L 335.10 http://www.cfcopies.com/V2/leg/leg_droi.php http://www.culture.gouv.fr/culture/infos-pratiques/droits/protection.htm Ecole Doctorale BioSE (Biologie-Santé-Environnement) Thèse Présentée et soutenue publiquement pour l’obtention du titre de DOCTEUR DE l’UNIVERSITE DE LORRAINE Mention : « Sciences de la Vie et de la Santé » Par Andréa GEOFFROY Conséquences d’une carence en donneurs de méthyles sur la différenciation neuronale et la plasticité : influence d’une supplémentation périnatale sur le développement cérébral. Le 08 Septembre 2015 Membres du jury : Rapporteurs : Pr. Marie-Laure Kottler PU-PH, U1075 INSERM, Caen, France Dr. Patrick Anglard DR, U7364 CNRS, Strasbourg, France Examinateurs : Dr. Hervé Moine DR, CNRS 7104 / INSERM U964, Strasbourg, France Pr. Jean-Louis Guéant PU-PH, U954 INSERM, Nancy, France Dr. Jean-Luc Daval DR, U954 INSERM, Nancy, France Directeur de thèse Dr. Carine Bossenmeyer-Pourié MCU, U954 INSERM, Nancy, France, Co-directeur de thèse Membres invités: Pr. Bruno Charpentier PR, U7365 CNRS, Nancy, France _________________________________________________________________________________ UMR 954 INSERM – «Nutrition, génétique et exposition aux risques environnementaux» 9 avenue de la Forêt de Haye-Faculté de Médecine - 54500 Vandoeuvre-lès-Nancy REMERCIEMENTS Je transmets mes sincères remerciements : A Madame le Professeur Marie-Laure Kottler et à Monsieur le Docteur Patrick Anglard pour avoir accepté d’être rapporteurs pour ma soutenance de thèse.
    [Show full text]
  • Chicken Linkage Disequilibrium Is Much More Complex Over Much Longer Distance Than Previously Appreciated
    Look Over the Horizon - Chicken Linkage Disequilibrium is Much More Complex Over Much Longer Distance than Previously Appreciated Ehud Lipkin ( [email protected] ) Hebrew University of Jerusalem Janet E. Fulton Hy-Line (United States) Jacqueline Smith University of Edinburgh David W. Burt University of Edinburgh Morris Soller Hebrew University of Jerusalem Research Article Keywords: Chicken, long-range linkage disequilibrium, QTL, F6, LD blocks Posted Date: June 17th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-598396/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/23 Abstract Background Appreciable Linkage Disequilibrium (LD) is commonly found between pairs of loci close to one another, decreasing rapidly with distance between the loci. This provides the basis studies to map Quantitative Trait Loci Regions (QTLRs), where it is custom to assume that the closest sites to a signicant markers are the prime candidate to be the causative mutation. Nevertheless, Long-Range LD (LRLD) can also be found among well-separated sites. LD blocks are runs of genomic sites all having appreciable LD with one another. High LD and LRLD are often separated by genomic sites with which they have practically no LD. Thus, not only can LD be found among distant loci, but also its pattern may be complex, comprised of fragmented blocks. Here, chicken LRLD and LD blocks, and their relationship with previously described Marek’s Disease (MD) QTLRs, were studied in an F6 population from a full-sib advanced intercross line, and in eight commercial pure layer lines.
    [Show full text]
  • The Transition from Primary Colorectal Cancer to Isolated Peritoneal Malignancy
    medRxiv preprint doi: https://doi.org/10.1101/2020.02.24.20027318; this version posted February 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with a hypermutant, hypermethylated state Sally Hallam1, Joanne Stockton1, Claire Bryer1, Celina Whalley1, Valerie Pestinger1, Haney Youssef1, Andrew D Beggs1 1 = Surgical Research Laboratory, Institute of Cancer & Genomic Science, University of Birmingham, B15 2TT. Correspondence to: Andrew Beggs, [email protected] KEYWORDS: Colorectal cancer, peritoneal metastasis ABBREVIATIONS: Colorectal cancer (CRC), Colorectal peritoneal metastasis (CPM), Cytoreductive surgery and heated intraperitoneal chemotherapy (CRS & HIPEC), Disease free survival (DFS), Differentially methylated regions (DMR), Overall survival (OS), TableFormalin fixed paraffin embedded (FFPE), Hepatocellular carcinoma (HCC) ARTICLE CATEGORY: Research article NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2020.02.24.20027318; this version posted February 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . NOVELTY AND IMPACT: Colorectal peritoneal metastasis (CPM) are associated with limited and variable survival despite patient selection using known prognostic factors and optimal currently available treatments.
    [Show full text]